Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc.

Jefferies analyst maintained a Buy rating on Protagonist Therapeutics today and set a price target of $121.00. The word on The Street in general, s...

Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCE...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HCA Healthcare (HCA) and Protagonist Therapeutics (P...

Analysts’ Top Healthcare Picks: HCA Healthcare (HCA), Protagonist Therapeutics (PTGX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX). John...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ArriVent BioPharma, Inc. (AVBP), Protagonist Therape...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$137.26	-2.59%	357.80K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTGX	$137.26	-2.6%	357.80K
3
4
5
6

PTGX

PTGX

Get Protagonist Therapeutics Inc. Data in Excel

Get Protagonist Therapeutics Inc. Data in Excel